HIMS has high short interest (28.5% of float) with 4.5 days to cover, and the author believes CEO attention to a paired token (BONER) signals a potential squeeze catalyst. The thesis relies on HIMS stock appreciation combined with leveraged token trading, but involves significant risks including counterparty risk with crypto pairings, illiquid token markets, and fee/slippage erosion of theoretical returns.

Post humorously suggests that 5,000 US sailors arriving in Thailand will dramatically increase demand for erectile dysfunction treatments, betting that $HIMS stock will decline due to oversupply of 'natural alternatives.' The thesis lacks credibility as a serious market analysis.

Investor is bullish on Nebius (NBIS) after selling Reddit and Hims positions to buy Jan 2027 call options, believing the recent selloff is overdone. Key risks include tech sector volatility, execution risk for Nebius, and the leverage inherent in options trading.

Former Netflix CFO David Wells bought $1.2M of HIMS stock at $24.23 on May 26, marking his first open-market purchase in nearly 5 years, despite the C-suite selling heavily and Q1 missing on earnings. The purchase suggests confidence in the company's GLP-1 transition, Wegovy ramp (125K shipments in 6 weeks), and international expansion (969% YoY growth), though near-term execution risk remains given the stock's current depressed valuation.

Author is bullish on $HIMS based on technical chart patterns showing a bounce off the 200-day moving average and potential golden cross, combined with the company's direct-to-consumer telehealth model for prescription medications. Key risks include the speculative nature of the trade, reliance on technical analysis alone, and the competitive telemedicine market.